Your session is about to expire
← Back to Search
Serotonin Receptor Agonist
Breast Cancer Pts with hyposexual desire disorder/HSDD for Breast Cancer
N/A
Waitlist Available
Led By Shari Goldfarb, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
Summary
The purpose of this study is to determine if it is feasible for women to take both Flibanserin and tamoxifen for the duration of the study. This study is also trying to find out if Flibanserin improves or has any effect on hyposexual desire disorder/HSDD in women who are taking tamoxifen for breast cancer.
Eligible Conditions
- Breast Cancer
- Low Libido
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Discontinuation rate of flibanserin in women with breast cancer on Tamoxifen with disease or medical induced hypoactive sexual desire disorder
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of flibanserin
Trial Design
1Treatment groups
Experimental Treatment
Group I: Breast Cancer Pts with hyposexual desire disorder/HSDDExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,956 Previous Clinical Trials
595,513 Total Patients Enrolled
205 Trials studying Breast Cancer
83,331 Patients Enrolled for Breast Cancer
Shari Goldfarb, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
8 Previous Clinical Trials
1,363 Total Patients Enrolled
7 Trials studying Breast Cancer
1,313 Patients Enrolled for Breast Cancer
Share this study with friends
Copy Link
Messenger